Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

55.23 +0.44 (+0.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
34 35 Next >
News headline image
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars? ↗
The three companies are spending big on IBD therapies. 
Via The Motley Fool
News headline image
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
News headline image
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy ↗
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
News headline image
Why Is Roivant Sciences (ROIV) Stock Up Today? ↗
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
News headline image
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
News headline image
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
News headline image
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
News headline image
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance ↗
The company's third-quarter sales also declined and came in light. 
Via Investor's Business Daily
News headline image
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗
Roche Holdings AG's (OTC: RHHBY) nine months  
Via Benzinga
News headline image
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:  
Via Benzinga
News headline image
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication ↗
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... 
Via Benzinga
News headline image
Why Is Alzheimer's Player Prothena Stock Trading Higher Today? ↗
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
News headline image
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points ↗
Broadcom and Arista lead five stocks sporting a flat base. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
From Genentech
Via Business Wire
News headline image
TPST Stock: 7 Things to Know About Tempest Therapeutics ↗
Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock. 
Via InvestorPlace
News headline image
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
News headline image
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
From Genentech
Via Business Wire
News headline image
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
From Genentech
Via Business Wire
News headline image
Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
From Genentech
Via Business Wire
News headline image
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update ↗
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
News headline image
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
From Genentech
Via Business Wire
News headline image
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich ↗
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
News headline image
2 Cathie Wood Stocks That Could Deliver Exponential Returns ↗
These two cutting-edge healthcare companies could be significantly undervalued right now. 
Via The Motley Fool
News headline image
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
From Genentech
Via Business Wire
News headline image
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
News headline image
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.